IV期ALK重排非小细胞肺癌的自然病程及与总生存相关因素
回顾性分析2009年至2017年11月在科罗拉多大学癌症中心接受ALK抑制剂治疗的110例IV期ALK阳性NSCLC患者,其中105例初始使用克唑替尼。中位随访47个月,中位OS为81个月;诊断时脑转移和IV期诊断年份未影响OS,受累器官数越多OS越差(每增加一个器官HR=1.49,p=0.002),培美曲塞为基础治疗每增加一个月死亡风险相对降低7%。
要点
- IV期ALK阳性NSCLC中位OS可达81个月(6.8年),中位随访47个月。
- 诊断时脑转移(HR=1.01,p=0.971)与IV期诊断年份(p=0.887)未影响OS。
- 每增加一个受累器官(含CNS)OS更差,HR=1.49(p=0.002)。
核心结论
- IV期ALK阳性NSCLC患者可获得延长的OS;诊断时脑转移不影响OS;IV期时受累器官数越多结局越差;培美曲塞延长获益与更好结局相关。
研究设计与样本
- 回顾性识别2009年至2017年11月在科罗拉多大学癌症中心接受ALK抑制剂治疗的IV期NSCLC患者,共110例ALK阳性患者,其中105例以克唑替尼为初始ALK抑制剂。
- 采用Kaplan-Meier法构建OS曲线,多因素Cox比例风险分析确定变量与OS的关系。
主要发现
- 中位随访47个月,自IV期诊断起中位OS为81个月(6.8年)。
- IV期诊断时脑转移与OS无关(HR=1.01,p=0.971),IV期诊断年份与OS无关(p=0.887)。
- IV期诊断时每增加一个受累器官(包括CNS)与更差OS相关(HR=1.49,p=0.002)。
- 培美曲塞为基础治疗每增加一个月,死亡风险相对降低7%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Clinical variables describing the natural history and longitudinal therapy outcomes of stage IV anaplastic lymphoma kinase gene rearrangement positive (ALK-positive) NSCLC and their relationship with long-term overall survival (OS) have not previously been described in detail. METHODS: Patients with stage IV NSCLC treated with an ALK inhibitor at the University of Colorado Cancer Center from 2009 through November 2017 were identified retrospectively. OS curves were constructed by using Kaplan-Meier methods. Multivariate Cox proportional hazard analysis was used to determine the relationship of variables with OS. RESULTS: Of the 110 patients with ALK-positive NSCLC who were identified, 105 received crizotinib as their initial ALK inhibitor. With a median follow-up time of 47 months, the median OS time from diagnosis of stage IV disease was 81 months (6.8 years). Brain metastases at diagnosis of stage IV disease (hazard ratio = 1.01, p = 0.971) and year of stage IV presentation (p = 0.887) did not influence OS. More organs with tumor at diagnosis of stage IV disease was associated with worse OS (HR = 1.49 for each additional organ with disease, including the CNS [p = 0.002]). Each additional month of pemetrexed-based therapy was associated with a 7% relative decrease in risk of death. CONCLUSION: Patients with stage IV ALK-positive NSCLC can have prolonged OS. Brain metastases at diagnosis of stage IV disease does not influence OS. Having more organs involved with tumor at stage IV presentation is associated with worse outcomes. Prolonged benefit from pemetrexed is associated with better outcomes.
引用
- Pacheco JM, Gao D, Smith D, et al. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 30599201. doi:10.1016/j.jtho.2018.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。